86.41
+0.55
(0.64%)
After Hours: 86.51
+0.10
(0.12%)
Jun 19, 4:49PM EDT
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 85.62 - 87.55 |
| 52 week | 42.47 - 96.25 |
| Open | 86.20 |
| Vol / Avg. | 8.35M/2.03M |
| Mkt cap | 26.37B |
| P/E | - |
| Div/yield | - |
| EPS | -0.43 |
| Shares | 305.13M |
| Beta | 0.85 |
| Inst. own | 94% |
Events
Aug 1, 2013
Q2 2013 Valeant Pharmaceuticals International, Inc. Earnings Release
Jun 11, 2013
Valeant Pharmaceuticals International, Inc. at Goldman Sachs Healthcare Conference
May 28, 2013
Valeant Pharmaceuticals International, Inc. Conference Call to Discuss its Definitive Agreement to Acquire Bausch + Lomb Holdings
May 21, 2013
Valeant Pharmaceuticals International, Inc. Annual Shareholder Meeting -
May 2, 2013
Q1 2013 Valeant Pharmaceuticals International, Inc. Earnings Conference Call
Apr 29, 2013
Q1 2013 Valeant Pharmaceuticals International, Inc. Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -2.58% | -3.27% |
| Operating margin | 8.95% | 1.68% |
| EBITD margin | - | 49.19% |
| Return on average assets | -0.62% | -0.75% |
| Return on average equity | -3.02% | -3.03% |
| Employees | 4,300 | - |
| Carbon Disclosure Rating | - | - |
Address
2150 St. Elzear Blvd.
WEST LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)
WEST LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. In April 2013, Valeant Pharmaceuticals International Inc acquired the entire share capital of Obagi Medical Products Inc. In June 2013, Hyperion Therapeutics Inc announced that the completion of its acquisition of BUPHENYL (sodium phenylbutyrate) Tablets and Powder from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International, Inc.
Officers and directors
| J. Michael Pearson | Chairman of the Board, Chief Executive Officer | |
| Howard Bradley Schiller | Chief Financial Officer, Executive Vice President, Director | |
| Robert Roswell Chai-Onn | Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development | |
| Laizer D. Kornwasser | Executive Vice President, Company Group Chairman | |
| Brian M. Stolz | Executive Vice President - Administration, Chief Human Capital Officer | |
| Ryan Weldon | Executive Vice President, Company Group Chairman | |
| Susan T. Hall | Senior Vice President, Global Head - Research and Development | |
| Robert A. Ingram | Lead Independent Director | |
| Ronald Harold Farmer | Independent Director | |
| Theo Melas-Kyriazi | Independent Director |